A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects With Selected Advanced Solid Tumors
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 30 Nov 2018
At a glance
- Drugs XmAb-23104 (Primary)
- Indications Acute myeloid leukaemia; B-cell lymphoma; Cancer; Haematological malignancies; Multiple myeloma; Neuroendocrine tumours
- Focus Adverse reactions
- Acronyms DUET-3
- Sponsors Xencor
- 23 Nov 2018 Status changed from planning to not yet recruiting.
- 01 Mar 2018 New trial record
- 27 Feb 2018 According to a Xencor media release, IND filling for this drug is expected in 2018 and initiation of this trial is expected in 2019.